These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 23685212)

  • 41. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1.
    Hultquist JF; Lengyel JA; Refsland EW; LaRue RS; Lackey L; Brown WL; Harris RS
    J Virol; 2011 Nov; 85(21):11220-34. PubMed ID: 21835787
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Signals in APOBEC3F N-terminal and C-terminal deaminase domains each contribute to encapsidation in HIV-1 virions and are both required for HIV-1 restriction.
    Song C; Sutton L; Johnson ME; D'Aquila RT; Donahue JP
    J Biol Chem; 2012 May; 287(20):16965-74. PubMed ID: 22451677
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of a novel WxSLVK motif in the N terminus of human immunodeficiency virus and simian immunodeficiency virus Vif that is critical for APOBEC3G and APOBEC3F neutralization.
    Dang Y; Wang X; Zhou T; York IA; Zheng YH
    J Virol; 2009 Sep; 83(17):8544-52. PubMed ID: 19535447
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
    Wang J; Shaban NM; Land AM; Brown WL; Harris RS
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evolutionarily conserved and non-conserved retrovirus restriction activities of artiodactyl APOBEC3F proteins.
    Jónsson SR; Haché G; Stenglein MD; Fahrenkrug SC; Andrésdóttir V; Harris RS
    Nucleic Acids Res; 2006; 34(19):5683-94. PubMed ID: 17038330
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Different interaction between HIV-1 Vif and its cellular target proteins APOBEC3G/APOBEC3F.
    Nagao T; Yamashita T; Miyake A; Uchiyama T; Nomaguchi M; Adachi A
    J Med Invest; 2010 Feb; 57(1-2):89-94. PubMed ID: 20299747
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Conserved and non-conserved features of HIV-1 and SIVagm Vif mediated suppression of APOBEC3 cytidine deaminases.
    Zhang W; Huang M; Wang T; Tan L; Tian C; Yu X; Kong W; Yu XF
    Cell Microbiol; 2008 Aug; 10(8):1662-75. PubMed ID: 18419775
    [TBL] [Abstract][Full Text] [Related]  

  • 48. APOBEC3 multimerization correlates with HIV-1 packaging and restriction activity in living cells.
    Li J; Chen Y; Li M; Carpenter MA; McDougle RM; Luengas EM; Macdonald PJ; Harris RS; Mueller JD
    J Mol Biol; 2014 Mar; 426(6):1296-307. PubMed ID: 24361275
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3).
    Pillai SK; Wong JK; Barbour JD
    Retrovirology; 2008 Mar; 5():26. PubMed ID: 18339206
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypes.
    Iwabu Y; Kinomoto M; Tatsumi M; Fujita H; Shimura M; Tanaka Y; Ishizaka Y; Nolan D; Mallal S; Sata T; Tokunaga K
    J Biol Chem; 2010 Nov; 285(46):35350-8. PubMed ID: 20833716
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function.
    Albin JS; Haché G; Hultquist JF; Brown WL; Harris RS
    J Virol; 2010 Oct; 84(19):10209-19. PubMed ID: 20686027
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HIV-1 Vif, APOBEC, and intrinsic immunity.
    Goila-Gaur R; Strebel K
    Retrovirology; 2008 Jun; 5():51. PubMed ID: 18577210
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity.
    Zhen A; Wang T; Zhao K; Xiong Y; Yu XF
    J Virol; 2010 Feb; 84(4):1902-11. PubMed ID: 19939923
    [TBL] [Abstract][Full Text] [Related]  

  • 54. APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.
    Chaipan C; Smith JL; Hu WS; Pathak VK
    J Virol; 2013 Jan; 87(1):444-53. PubMed ID: 23097438
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of APOBEC3F Gene Variation in HIV-1 Disease Progression and Pneumocystis Pneumonia.
    An P; Penugonda S; Thorball CW; Bartha I; Goedert JJ; Donfield S; Buchbinder S; Binns-Roemer E; Kirk GD; Zhang W; Fellay J; Yu XF; Winkler CA
    PLoS Genet; 2016 Mar; 12(3):e1005921. PubMed ID: 26942578
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding.
    Mehle A; Wilson H; Zhang C; Brazier AJ; McPike M; Pery E; Gabuzda D
    J Virol; 2007 Dec; 81(23):13235-41. PubMed ID: 17898068
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F.
    Yamashita T; Kamada K; Hatcho K; Adachi A; Nomaguchi M
    Microbes Infect; 2008; 10(10-11):1142-9. PubMed ID: 18603011
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HIV restriction by APOBEC3 in humanized mice.
    Krisko JF; Martinez-Torres F; Foster JL; Garcia JV
    PLoS Pathog; 2013 Mar; 9(3):e1003242. PubMed ID: 23555255
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vif determines the requirement for CBF-β in APOBEC3 degradation.
    Yoshikawa R; Takeuchi JS; Yamada E; Nakano Y; Ren F; Tanaka H; Münk C; Harris RS; Miyazawa T; Koyanagi Y; Sato K
    J Gen Virol; 2015 Apr; 96(Pt 4):887-892. PubMed ID: 25516542
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differences in APOBEC3G expression in CD4+ T helper lymphocyte subtypes modulate HIV-1 infectivity.
    Vetter ML; Johnson ME; Antons AK; Unutmaz D; D'Aquila RT
    PLoS Pathog; 2009 Feb; 5(2):e1000292. PubMed ID: 19197360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.